Waverley Pharma Inc. (FRA:5GZ)

Market Cap	1.00M -72.3%
Revenue (ttm)	921.24K +2,016.3%
Net Income	-224.63K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0120
Previous Close	0.0120
Day's Range	0.0120 - 0.0120
52-Week Range	0.0040 - 0.0140
Beta	n/a
RSI	89.67
Earnings Date	Apr 28, 2026

About Waverley Pharma

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GZ

Financial Performance

In 2024, Waverley Pharma's revenue was 475,373, an increase of 15.36% compared to the previous year's 412,090. Losses were -947,077, -57.42% less than in 2023.

Financial numbers in CAD